A Phase 4 interventional study of Lisdexamfetamine dimesylate and Methylphenidate Hydrochloride in Attention-deficit/Hyperactivity Disorder, sponsored by Shire. Completed at 95 sites in 5 countries. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-10.
Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one has the largest enrollment, is one of 3 that started in 2012, is one of 23 in phase 4, and was the 33rd registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 8 yrs–198 mo
By country, each count listing its studies:
lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 15 · Phase 4 23
First in 2004; this study’s year is marked. 3 started in 2012.
This study's enrollment of 549 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 48 across the 51 interventional studies. Of the 49 that completed or were terminated, 37 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
57 studies in Attention Deficit Disorder with Hyperactivity by Takeda: none open now, none under way, none of them phase 3. Of 55 finished, 37 (67%) have results posted.
Among the 57 studies in Attention Deficit Disorder with Hyperactivity by Takeda, this one has the largest enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2012, is one of 8 in phase 4, and was the 41st registered.
Takeda’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 57 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lisdexamfetamine dimesylate
Drug: Methylphenidate Hydrochloride
Drug: Placebo
Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
Also known as: SPD489, Vyvanse, LDX
Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
Also known as: Concerta, OROS-MPH
Daily oral dosing in the AM for 6 weeks
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 6
The ADHD-RS-IV was developed to measure the behaviors of children with ADHD and is commonly used in clinical studies of ADHD. The ADHD-RS-IV consisted of 18 items designed to reflect current symptomatology of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR) criteria. Each item was scored on a 4-point scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54, Higher score = more severe symptoms.
Time frame: Baseline, Week 6
Percentage of Participants With an Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 6
The Clinical Global Impressions Scale permits a global evaluation of the participant's severity of illness and improvement over time. The scale included a severity of illness item and a global improvement item. The investigator performed the CGI-I to rate the improvement of a participant's ADHD symptoms based on a 7-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse.). Percentage of participants with an improved measurement (response of very much improved and much improved) is reported.
Time frame: Week 6
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events between first dose of double-blind investigational product and up to 3 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to 3 days after last dose (last dose at Week 6)
Change From Baseline in Blood Pressure at Week 6
Time frame: Baseline, Week 6
Change From Baseline in Pulse Rate at Week 6
Time frame: Baseline, Week 6
The study was conducted at 77 sites in the United States, Canada, and Europe.
| Milestone | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate |
|---|---|---|---|
| Started | 110 | 218 | 219 |
| Completed | 97 | 181 | 186 |
| Not completed | 13 | 37 | 33 |
| Withdrew: Adverse event | 1 | 15 | 14 |
| Withdrew: Protocol violation | 3 | 3 | 3 |
| Withdrew: Lack of efficacy | 4 | 3 | 1 |
| Withdrew: Withdrawal by subject | 1 | 9 | 6 |
| Withdrew: Lost to follow-up | 1 | 3 | 6 |
| Withdrew: Other | 3 | 4 | 3 |
The ADHD-RS-IV was developed to measure the behaviors of children with ADHD and is commonly used in clinical studies of ADHD. The ADHD-RS-IV consisted of 18 items designed to reflect current symptomatology of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR) criteria. Each item was scored on a 4-point scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54, Higher score = more severe symptoms.
| units on a scale | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate |
|---|---|---|---|
| Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 6 | -17 ± 1.03 | -25.4 ± 0.74 | -22.1 ± 0.73 |
The Clinical Global Impressions Scale permits a global evaluation of the participant's severity of illness and improvement over time. The scale included a severity of illness item and a global improvement item. The investigator performed the CGI-I to rate the improvement of a participant's ADHD symptoms based on a 7-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse.). Percentage of participants with an improved measurement (response of very much improved and much improved) is reported.
| percentage of participants | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate |
|---|---|---|---|
| Percentage of Participants With an Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 6 | 50 | 81.4 | 71.3 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events between first dose of double-blind investigational product and up to 3 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| participants | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate |
|---|---|---|---|
| Participants with TEAEs | 49 | 145 | 129 |
| Participants with serious TEAEs | 1 | 1 | 1 |
| millimeter of mercury (mmHg) | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate |
|---|---|---|---|
| Systolic blood pressure | -1 ± 9.88 | 1.5 ± 9.56 | 2.4 ± 9.97 |
| Diastolic blood pressure | -0.1 ± 8.1 | 3.4 ± 8.15 | 3.5 ± 8.59 |
| Beats per minute | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate |
|---|---|---|---|
| Change From Baseline in Pulse Rate at Week 6 | 2.4 ± 10.81 | 6.7 ± 12.46 | 8.2 ± 12.7 |
Collected over Baseline up to 3 days after last dose (last dose at Week 6). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/110 (0.9%) | 32/110 (29.1%) |
| Lisdexamfetamine Dimesylate | — | 1/218 (0.5%) | 113/218 (51.8%) |
| Methylphenidate | — | 1/219 (0.5%) | 99/219 (45.2%) |
| Event | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate |
|---|---|---|---|
| Psychotic episodePsychiatric disorders | 1/110 | 0/218 | 0/219 |
| Suicidal ideationPsychiatric disorders | 0/110 | 1/218 | 0/219 |
| AppendicitisInfections and infestations | 0/110 | 0/218 | 1/219 |
| Event | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate |
|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 11/110 | 69/218 | 51/219 |
| HeadacheNervous system disorders | 9/110 | 33/218 | 35/219 |
| Weight decreasedInvestigations | 0/110 | 23/218 | 11/219 |
| InsomniaPsychiatric disorders | 3/110 | 17/218 | 17/219 |
| Dry mouthGastrointestinal disorders | 1/110 | 16/218 | 7/219 |
| IrritabilityGeneral disorders | 7/110 | 11/218 | 15/219 |
| DizzinessNervous system disorders | 0/110 | 12/218 | 11/219 |
| NauseaGastrointestinal disorders | 3/110 | 11/218 | 11/219 |
| Abdominal pain upperGastrointestinal disorders | 2/110 | 11/218 | 8/219 |
The Safety set consisted of all participants in the Randomized set (all screened participants for whom a randomization number was generated) who took at least 1 dose of investigational product.
| Age, Categorical(Participants) | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate | Total |
|---|---|---|---|---|
| <=18 years | 110 | 218 | 219 | 547 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate | Total |
|---|---|---|---|---|
| Mean | 14.7 ± 1.37 | 14.6 ± 1.38 | 14.7 ± 1.42 | 14.7 ± 1.40 |
| Sex: Female, Male(Participants) | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate | Total |
|---|---|---|---|---|
| Female | 34 | 83 | 69 | 186 |
| Male | 76 | 135 | 150 | 361 |
| Attention-deficit/Hyperactivity Disorder (ADHD) Subtype(Participants) | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate | Total |
|---|---|---|---|---|
| Predominantly Inattentive | 40 | 70 | 71 | 181 |
| Predominantly Hyperactive/Impulsive | 2 | 2 | 4 | 8 |
| Combined Subtype | 68 | 146 | 144 | 358 |
| Clinical Global Impressions - Severity of Illness (CGI-S)(Participants) | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate | Total |
|---|---|---|---|---|
| Borderline mentally ill | 1 | 0 | 0 | 1 |
| Mildly ill | 2 | 4 | 1 | 7 |
| Moderately ill | 60 | 93 | 115 | 268 |
| Markedly ill | 41 | 106 | 90 | 237 |
| Severely ill | 6 | 15 | 13 | 34 |
| Attention-deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score(units on a scale) | Placebo | Lisdexamfetamine Dimesylate | Methylphenidate | Total |
|---|---|---|---|---|
| Mean | 36.1 ± 5.91 | 37.2 ± 6.46 | 36.9 ± 6.42 | 36.9 ± 6.34 |
Ran from Apr 2012 to primary completion in May 2014, 25 months.
Results were first posted in Mar 2015, 9 months after primary completion.
Of 62 phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine
Attention Deficit Disorder with Hyperactivity →